EndoTODAY | EndoATLAS | OPD

Parasite | Eso | Sto | Cancer | ESD

Boxim | DEX | Sono | Schedule

Home | Recent | Blog | Links

EndoTODAY ³»½Ã°æ ±³½Ç


[³»½Ã°æ ÁøÁ¤ - ¸¶Ãë°ú ±è´ö°æ ±³¼ö´Ô ³í¹®°ú °ü·Ã ³íÀÇ (2015)]

1. [2015-2-6. Áß¾ÓÀϺ¸] 42.9%´Â Ç¥Áظ¶Ãë °ü¸®¸¸ Ç߾ ¿¹¹æ °¡´ÉÇß´Ù

2015³â 2¿ù 6ÀÏ Áß¾ÓÀϺ¸¿¡ ÀÚ±ØÀûÀÎ Á¦¸ñÀÇ ±â»ç°¡ ½Ç·È½À´Ï´Ù. »ï¼º¼­¿ïº´¿ø ¸¶ÃëÅëÁõÀÇÇаú ±è´ö°æ ±³¼ö´ÔÀÇ ÃÖ±Ù ³í¹®(Roh WS. J Korean Med Sci 2015)À» ¼Ò°³ÇÏ´Â ³»¿ëÀ̾ú½À´Ï´Ù.

±¹³» º´¡¤ÀÇ¿ø¿¡¼­ ÃÖ±Ù 5³â°£ ¸¶Ãë °ü·Ã ÀÇ·á »ç¸Á»ç°í°¡ 82°Ç¿¡ ´ÞÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù. ƯÈ÷ ºñ±³Àû ¾ÈÀüÇÏ´Ù°í ¿©°ÜÁö´Â ¼ö¸é¸¶Ãë·Î ÀÎÇÑ »ç¸Á»ç°íµµ ÀûÁö ¾Ê¾Ò´Ù. »ï¼º¼­¿ïº´¿ø ¸¶ÃëÅëÁõÀÇÇаú ±è´ö°æ ±³¼ö ¿¬±¸ÆÀÀº 2009³â 7¿ùºÎÅÍ 2014³â 6¿ù±îÁö ±¹³» ÀÇ·á±â°ü¿¡¼­ ¹ß»ýÇÑ ¸¶Ãë °ü·Ã ÀÇ·áºÐÀï Áß ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ°¡ ÀÚ¹®ÇÑ 105°ÇÀ» ºÐ¼®ÇØ ´ëÇÑÀÇÇÐȸ ±¹Á¦ÇмúÁö(JKMS) 2¿ùÈ£¿¡ ¹ßÇ¥Çß´Ù. ¿¬±¸ °á°ú¿¡ µû¸£¸é ÀÌ ±â°£¿¡ ¸¶Ãë °ü·Ã ÀÇ·á»ç°í¸¦ ´çÇÑ È¯ÀÚ 105¸í Áß 82¸í(78.1%)ÀÌ »ç¸ÁÇß´Ù. 60¼¼ ÀÌÇÏ È¯ÀÚ°¡ 82.9%¿´À¸¸ç ÀÌµé °¡¿îµ¥ 90.5%´Â ¹Ì±¹¸¶Ãë°úÇÐȸ ½Åüµî±ÞÁö¼ö 1¶Ç´Â 2ÀÇ °Ç°­ÇÑ »ç¶÷µéÀ̾ú´Ù.

¿¬±¸ÆÀÀº ¡°Àüü 105°Ç Áß 42.9%´Â Ç¥ÁØÀûÀÎ ¸¶Ãë °ü¸®¸¸ Ç߾ ¿¹¹æ °¡´ÉÇÑ °ÍÀ¸·Î ÀÇ·á»ç¾ÈÀ» °¨Á¤ÇÑ ¸¶ÃëÅëÁõÀÇÇаú Àü¹®ÀÇ¿¡ ÀÇÇØ ÆÇÁ¤µÆ´Ù¡±°í ÀüÇß´Ù.¸¶Ãë Á¾·ùº°·Î º¸¸é Àü½Å¸¶Ãë°¡ 50°Ç(47.6%)À¸·Î °¡Àå ¸¹¾Ò´Ù. ¼ö¸é¸¶Ãëµµ 39°Ç(37.1%)À̳ª µÆ´Ù. ¿¬±¸ÆÀÀº ¡°ÁÖ¸ñÇÒ ¸¸ÇÑ ³»¿ëÀº ÀϹÝÀε鿡°Ô Àü½Å¸¶Ãë¿¡ ºñÇØ »ó´ëÀûÀ¸·Î ¾ÈÀüÇÏ´Ù°í ¾Ë·ÁÁ® ÀÖ´Â ¼ö¸é¸¶Ãë°¡ Àüü ÀÇ·Ú °Ç Áß 37.1%¸¦ Â÷ÁöÇÏ°í ÀÖ´Ù´Â Á¡¡±À̶ó°í ¸»Çß´Ù. ƯÈ÷ ¼ö¸é¸¶Ãë »ç°í 39°Ç Áß 30°Ç(76.9%)Àº »ç¸ÁÀ¸·Î À̾îÁ³´Ù. ÀÌ´Â Àü½Å¸¶Ãë »ç°í 50°Ç¿¡¼­ 41°Ç(82.0%)ÀÌ »ç¸ÁÇÑ °Í°ú ºñ½ÁÇÑ ¼öÄ¡´Ù. »ç¸Á ¿øÀÎÀ¸·Î´Â ¼ö¸é¸¶ÃëÁ¦ °ú ¿ë·® ÁÖ»ç·Î ÀÎÇÑ ±âµµÆó¼â ¶Ç´Â È£ÈíºÎÀüÀÌ 24°ÇÀ¸·Î °¡Àå ¸¹¾Ò´Ù.

´õ¿íÀÌ ¼ö¸é¸¶Ãë »ç°íÀÇ 92.3%(36°Ç)´Â ºñ¸¶ÃëÅëÁõÀÇÇаú Àü¹®ÀÇ°¡ ¸¶ÃëÁ¦¸¦ ÁÖ»çÇÑ °æ¿ì¿´´Ù. ¿¬±¸ÆÀÀº "ÀÌ´Â ½Ã¼ú°ú ¹«°üÇÑ µ¶¸³ÀûÀÎ ¼ö¸é ¸¶Ãë Àü´ã ÀÇ·áÁøÀÌ ¹Ýµå½Ã Á¸ÀçÇØ¾ß ÇÑ´Ù´Â ±âº» ÀÓ»óÁöħÀ» ÁöÅ°Áö ¾ÊÀº °Í"À̶ó°í ¼³¸íÇß´Ù. ¶ÇÇÑ ¼ö¸é¸¶ÃëÀÇ 89.7%(35°Ç)¿¡¼­ ÇÁ·ÎÆ÷ÆúÀÌ ´Üµ¶ ¶Ç´Â Ÿ ¾àÁ¦¿Í µ¿¹Ý »ç¿ëµÈ °ÍÀ¸·Î È®ÀεƴÙ. ÀÌ´Â ¹Ì´ÙÁ¹¶÷°ú °°Àº ÀüÅëÀûÀÎ ÁøÁ¤Á¦¿¡ ºñÇØ ÇÁ·ÎÆ÷ÆúÀÌ È£Èí¾ïÁ¦¸¦ ´õ¿í ½ÉÇÏ°Ô À¯¹ßÇÑ´Ù´Â »ç½ÇÀ» ´Ù½Ã ÇÑ ¹ø ÀÔÁõÇÏ´Â »ç·Ê¶ó´Â ºÐ¼®ÀÌ´Ù. ¼ö¸é¸¶Ãë °ü¸®µµ ´ëºÎºÐ ºÎÀûÀýÇÑ °ÍÀ¸·Î Á¶»çµÆ´Ù. 92.3%¿¡¼­ ¸¶Ãë Àü ȯÀÚ Æò°¡±â·ÏÀÌ ¾ø¾úÀ¸¸ç, 98.7%¿¡¼± ¾Æ¿¹¡¡¼ö¸é¸¶Ãë ±â·ÏÁö°¡ ¾ø¾ú´Ù. 6°Ç(15.4%)Àº ¼ö¸é¸¶Ãë Áß È¯ÀÚ °¨½Ã ÀåÄ¡ »ç¿ëÀÌ ÀüÇô ¾ø¾ú°í, 24°Ç(61.5%)ÀÇ °æ¿ì ¼ö¸é¸¶Ãë Áß º¸Á¶ÀûÀÎ »ê¼Ò °ø±ÞÀÌ ¾ø¾ú´Ù.

ÀÌó·³ ¼ö¸é¸¶Ãë¿¡ ´ëÇÑ ³í¶õÀÌ ÀÕµû¸£ÀÚ ¼ö¸é¸¶Ãë¿¡ ´ëÇÑ ±ÔÁ¦¸¦ Àü½Å¸¶Ãë ¼öÁØÀ¸·Î °­È­ÇØ¾ß ÇÑ´Ù´Â ¿©·ÐÀÌ °Å¼¼°Ô ÀÏ°í ÀÖ´Ù. ÇÏÁö¸¸ ÀϺΠºñ¸¶ÃëÅëÁõÀÇÇаú Àü¹®ÀǵéÀº ¹ß²öÇÏ´Â ºÐÀ§±â´Ù. Ÿ°ú ÀÇ»çÀÇ ±ÇÀÍÀ» ħÇØÇÏ´Â ¿ä¼Ò¶ó´Â ÆÇ´Ü¿¡¼­´Ù. ´ëÇÑÆòÀÇ»çȸ´Â ¡°°£´ÜÇÑ ¼ö¸é¸¶Ãëµµ ¸¶Ãë°ú ÀÇ»ç ÀÔȸ ÇÏ¿¡ ÇØ¾ß ÇÑ´Ù´Â ÁÖÀåÀº »ç½Ç»ó Ÿ°ú ÀÇ»çÀÇ ¼ö¸é¸¶ÃëÁ¦ »ç¿ëÀ» Àü¸é ±ÝÇÑ´Ù´Â ¾ê±â¡±¶ó°í ÁöÀûÇß´Ù. ÃÖ±Ù ¼ö¸é¸¶Ãë »ç¸Á»ç°í°¡ ¸î °Ç ÀÖ¾ú´Ù´Â °ÍÀ» ±Ù°Å·Î Ÿ°ú ÀÇ»çÀÇ ÇàÀ§¸¦ ±ÝÁöÇÏ´Â °ÍÀº Æø·ÂÀ̶õ ÁÖÀåÀÌ´Ù. ÆòÀÇ»çȸ´Â ¡°±³Åë»ç°í°¡ ¸î °Ç ÀÖ¾ú´Ù°í ÀÚµ¿Â÷¸¦ ÀüºÎ ¾ø¾ÖÀÚ´Â °Í°ú ¶È°°Àº ¹ß»ó¡±À̶ó¸ç ¡°Å¸°úÀÇ»çÀÇ Á÷¾÷¼öÇàÀÇ ÀÚÀ¯¸¦ Àü¸éÀ¸·Î ħÇØÇÏ´Â ¸¶ÃëÅëÁõÀÇÇаúÀÇ °úº°À̱âÁÖÀǸ¦ °­·ÂÈ÷ ±ÔźÇÑ´Ù¡±°í ÇÇ·ÂÇß´Ù.

¾Æ·¡´Â ³í¹® ÃÊ·ÏÀÔ´Ï´Ù (Roh WS. J Korean Med Sci 2015). ¸¶Ãë°ú µ¥ÀÌŸº£À̽º¸¦ ºÐ¼®ÇÑ ³í¹®ÀÔ´Ï´Ù.

Analysis of Anesthesia-related Medical Disputes in the 2009-2014 Period Using the Korean Society of Anesthesiologists Database

Using the Korean Society of Anesthesiologists database of anesthesia-related medical disputes (July 2009-June 2014), causative mechanisms and injury patterns were analyzed. In total, 105 cases were analyzed. Most patients were aged < 60 yr (82.9%) and were classified as American Society of Anesthesiologists physical status ¡Â II (90.5%). In 42.9% of all cases, the injuries were determined to be 'avoidable' if the appropriate standard of care had been applied. Sedation was the sec most common type of anesthesia (37.1% of all cases), following by general anesthesia. Most sedation cases (27/39, 69.2%) showed a common lack of vigilance: no pre-procedural testing (82.1%), absence of anesthesia record (89.7%), and non-use of intra-procedural monitoring (15.4%). Most sedation (92.3%) was provided simultaneously by the non-anesthesiologists who performed the procedures. After the resulting injuries were grouped into four categories (temporary, permanent/minor, permanent/major, and death), their causative mechanisms were analyzed in cases with permanent injuries (n=20) and death (n=82). A 'respiratory events' was the leading causative mechanism (56/102, 54.9%). Of these, the most common specific mechanism was hypoxia secondary to airway obstruction or respiratory depression (n=31). The sec most common damaging event was a 'cardiovascular events' (26/102, 25.5%), in which myocardial infarction was the most common specific mechanism (n=12). Our database analysis demonstrated several typical injury profiles (a lack of vigilance in seemingly safe procedures or sedation, non-compliance with the airway management guidelines, and the prevalence of myocardial infarction) and can be helpful to improve patient safety.


2. ¸¶ÃëÅëÁõÀÇÇаú ³í¹®(Roh WS. J Korean Med Sci 2015)¿¡ ´ëÇÑ ÀÌÁØÇà comment [2015-2-8]

¶Ç ÇѹÙÅÁ Å« ½Î¿òÀÌ ¹ú¾îÁú ±â¼¼ÀÔ´Ï´Ù. PropofolÀ» ÀÌ¿ëÇÑ ÁøÁ¤À» ´©°¡ ÇÒ °ÍÀΰ¡ÀÇ ¹®Á¦·Î ½Î¿ì´Â °ÍÀÌÁö¿ä. ±×·±µ¥ Àú´Â ´©°¡ ÇÒ °ÍÀΰ¡´Â º»ÁúÀûÀÎ ¹®Á¦°¡ ¾Æ´Ï¶ó°í »ý°¢ÇÕ´Ï´Ù. ÇÙ½ÉÀº '¾î¶»°Ô ¾ÈÀüÀ» ´ãº¸ÇÒ °ÍÀΰ¡'ÀÔ´Ï´Ù. ´©°¡ Çصµ »ó°ü ¾ø½À´Ï´Ù. ¾ÈÀü¸¸ ÇÏ´Ù¸é...

±â»ç ³»¿ë¿¡ µû¸£¸é "½Ã¼ú°ú ¹«°üÇÑ µ¶¸³ÀûÀÎ ¼ö¸é ¸¶Ãë Àü´ã ÀÇ·áÁøÀÌ ¹Ýµå½Ã Á¸ÀçÇØ¾ß ÇÑ´Ù"´Â ÁÖÀåÀÌ "¸¶Ãë°ú Àǻ縸 propofolÀ» ½á¾ß ÇÑ´Ù"´Â ÁÖÀå°ú µ¿ÀϽõǰí ÀÖ½À´Ï´Ù. ±×·±µ¥ ÀÌ´Â ÀüÇô ´Ù¸¥ À̾߱âÀÔ´Ï´Ù. ÀûÀýÇÑ ±³À°°ú ÃæºÐÇÑ °æÇèÀ» °¡Áø ÀÇ·áÁøÀÌ ½Ã¼ú°ú ¹«°üÇÏ°Ô ÁøÁ¤À» ´ã´çÇÏ¸é µÇ´Â °ÍÀÔ´Ï´Ù. Áï ´Ù¸¥ ÀÏÀº ÇÏÁö ¾Ê°í ¿ÀÁ÷ ÁøÁ¤¸¸ ´ã´çÇÏ´Â »ç¶÷ÀÌ ÀÖ¾î¾ß ÇÑ´Ù´Â °ÍÀÌÁö¿ä. ¸¶Ãë°ú Àǻ翩µµ ÁÁ°í ³»°ú Àǻ翩µµ ÁÁ°í ÀϹÝÀǵµ ÁÁ½À´Ï´Ù. (°£È£»ç ȤÀº °£È£ Á¶¹«»çµµ »ó°ü¾ø´ÂÁö´Â Àú´Â Àß ¸ð¸£°Ú½À´Ï´Ù.) ³»½Ã°æ ½Ã¼úÀ» ÇÏÁö ¾Ê°í ÁøÁ¤¸¸ ´ã´çÇÏ´Â »ç¶÷ÀÌ ÁߴܾøÀÌ Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ(uninterrupted continous monitoring)À» ÇÑ´Ù¸é propofol sedationÀº Áö±Ýº¸´Ù ÈξÀ ¾ÈÀüÇØÁú °ÍÀÔ´Ï´Ù. ³»½Ã°æÀ» Çϸ鼭 °¡²û Èú²ý ȯÀÚ »óŸ¦ ÃÄ´Ùº¸´Â °ÍÀº ºÒÃæºÐÇÕ´Ï´Ù. ´©±º°¡ ´Ù¸¥ ÀÏÀ» ÇÏÁö ¾ÊÀ¸¸é¼­ ȯÀÚ°¡ ¿ÏÀüÈ÷ ±ý ¶§±îÁö °è¼Ó ÁöÄѺ¸´Â ÀÇ·áÁøÀÌ ÀÖ¾î¾ß ÇÕ´Ï´Ù. ÀÌ·± ÀÔÀå¿¡¼­ 2³â Àü ¹àÈù ¹Ù ÀÖ´Â ÀúÀÇ position statement´Â ¿©ÀüÈ÷ À¯È¿ÇÕ´Ï´Ù.

* Position statement: Àú´Â ÇÁ·ÎÆ÷ÆúÀ» »ç¿ëÇÑ ³»½Ã°æ ÁøÁ¤¿¡ ¹Ý´ëÇÏÁö ¾Ê½À´Ï´Ù. »çÀü Æò°¡¿Í Áغñ°¡ Àß µÇ¾î¾ßÇϸç, ½Ã¼ú µµÁß ¹× ½Ã¼ú ÈÄ ¸ð´ÏÅ͸µÀÌ ¿øÄ¢´ë·Î ¾ÈÀüÇÏ°Ô ÁøÇàµÇ¾î¾ß ÇÑ´Ù´Â Á¡À» °­Á¶ÇÒ »ÓÀÔ´Ï´Ù. ¾ÈÀü¼ºÀÌ ÃæºÐÈ÷ È®º¸µÇÁö ¸øÇÑ ¾Æ½½¾Æ½½ÇÑ ÁøÁ¤¿¡´Â ¹Ý´ëÇÕ´Ï´Ù. [2013-6-14. ÀÌÁØÇà]

2015³â 2¿ù 8ÀÏ ÇöÀç Á¦°¡ »ý°¢ÇÏ´Â ¹Ù¸¦ ´Ù½Ã Çѹø °£´ÜÈ÷ Á¤¸®Çϸé ÀÌ·¸½À´Ï´Ù. "¿ì¸®³ª¶ó Çö½Ç¿¡¼­ propofolÀ» »ç¿ëÇÑ ¼ö¼úÀ» À§Çؼ­´Â ¸¶Ãë°ú Àǻ簡 ÇÊ¿äÇÕ´Ï´Ù. ±×·¯³ª ªÀº Áø´Ü³»½Ã°æ±îÁö ¸¶Ãë°ú Àǻ簡 ÇÊ¿äÇÏ´Ù°í ÁÖÀåÀº ¹«¸®ÀÔ´Ï´Ù. ¹°·Ð ¸¶Ãë°ú Àǻ簡 ¾ø´õ¶óµµ ÃæºÐÇÑ ¾ÈÀü ´ëÃ¥Àº ÇÊ¿äÁ¶°ÇÀÔ´Ï´Ù."

ÇÑ °¡Áö ´õ. À̹ø ±â»ç¿¡¼­ ¾ð±ÞµÈ ¹Ù¿Í °°ÀÌ propofol ¸¶Ãë »ç°í´Â Àþ°í °Ç°­ÇÑ »ç¶÷¿¡¼­ ¸¹ÀÌ ¹ß»ýÇÕ´Ï´Ù. ½ÉÆó±â´É¿¡ ¹®Á¦°¡ ÀÖ´Â °íÀ§Çè ȯÀÚ¿¡¼­ ¹ß»ýÇÏ´Â °ÍÀÌ ¾Æ´Õ´Ï´Ù. ´ëºÎºÐ ȯÀÚ ¹®Á¦°¡ ¾Æ´Õ´Ï´Ù. Propofol °ú·® Åõ¿©¿Í monitoring ºÎÁ·ÀÌ ¹®Á¦ÀÏ »ÓÀÔ´Ï´Ù. ÀþÀº »ç¶÷¿¡¼­´Â ¿ë·®À» ¿Ã¸®±â ½¬¿ì¹Ç·Î »ç°í°¡ ¸¹Àº °ÍÀÔ´Ï´Ù. ¹æ½ÉÀÌ ¿øÀÎÀ̶ó´Â °ÍÀÌÁö¿ä. µû¶ó¼­ ÀûÀýÈ÷ ÁÖÀÇÇϸé ÈξÀ ´õ ¾ÈÀüÇØ Áú ¼ö ÀÖ½À´Ï´Ù.


3. ÀÌÁØÇà comment [2015-2-8]¿¡ ´ëÇÑ ±è´ö°æ ±³¼ö´ÔÀÇ ´äº¯ [2015-2-9]

À̹ø ±â»ç¿Í ±×¿¡ ´ëÇÑ ÀúÀÇ ÀÇ°ßÀ» ÇÑ ¸¶Ãë°ú ¼±»ý´Ô²² º¸¿©µå·È°í ¾Æ·¡¿Í °°Àº ´äº¯À» ¹Þ¾Ò½À´Ï´Ù. ¸¶Ãë°ú ¼±»ý´ÔµéÀº ´Ù¸¥ Àü°ø ¼±»ý´ÔµéÀÇ propofol »ç¿ë¿¡ ¹Ý´ëÇÏÁö ¾Ê´Â´Ù°í ÇÕ´Ï´Ù. Àü¹®°¡·Î¼­ ¾ÈÀüÀ» À§ÇÑ ÃÖ¼ÒÇÑÀÇ °¡À̵å¶óÀÎÀ» ÁöÅ°µµ·Ï ±Ç°íÇÏ°í ÀÖÀ» »ÓÀÎ µí ÇÕ´Ï´Ù. ´ÜÁö ¸¶Ãë Àü¹®°¡°¡ ½Ã¼ú¿¡ Âü¿©ÇÒ ¶§¿¡´Â µû·Î ¼ö°¡¸¦ Àû¿ëÇÏÀÚ´Â °ÍÀ̾ú½À´Ï´Ù. Àú´Â ¸¶Ãë°úÀÇ ÀÔÀå¿¡ ¿ø·ÐÀûÀ¸·Î Âù¼ºÇÕ´Ï´Ù. Àü¹®°¡ÀÇ °æÇè°ú ³ë·ÂÀº Á¸ÁßÇØÁÖ´Â °ÍÀÌ ¸Â±â ¶§¹®ÀÔ´Ï´Ù. ´Ù¸¸ "°£È£»ç"·Î ¸í½ÃµÈ ºÎºÐÀÌ Àֱ⠶§¹®¿¡ "°£È£Á¶¹«»ç"°¡ ÁÖ ÀηÂÀÎ °³¾÷°¡ ¼±»ý´ÔµéÀÇ ¹Ý´ë°¡ ¿¹»óµË´Ï´Ù. ¸¶Ãë°ú ¼±»ý´ÔÀÇ ÀÇ°ßÀ» ¾Æ·¡¿¡ ¿Å±é´Ï´Ù.

[2015-2-9. ¸¶Ãë°ú ¼±»ý´ÔÀÇ ´äº¯]

´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸÀÇ ÀÔÀåÀº ¾Æ·¡¿Í °°½À´Ï´Ù.

1. ÇÁ·ÎÆ÷Æú ¼ö¸é¸¶Ãë´Â Ÿ ÁøÁ¤Á¦ »ç¿ë ¼ö¸é¸¶Ãë¿Í ºÐ¸®ÇÏ¿© Àü½Å¸¶Ãë¿¡ ÁØÇÏ´Â °ü¸®°¡ ÇÊ¿äÇÏ´Ù.

2. ÇÁ·ÎÆ÷Æú ¼ö¸é¸¶Ãë ½Ã´Â ¹Ýµå½Ã "½Ã¼ú°ú ¹«°üÇÑ µ¶¸³ÀûÀÎ ¼ö¸é ¸¶Ãë Àü´ã ÀÇ·áÁø(¼ÒÁ¤ÀÇ ±³À°À» ¹ÞÀº ÀÇ»ç ¶Ç´Â °£È£»ç)"ÀÌ ¹Ýµå½Ã Á¸ÀçÇØ¾ß ÇÑ´Ù.

¸¶ÃëÅëÁõÀÇÇаú Àü¹®ÀǸ¸ÀÌ ÇÁ·ÎÆ÷Æú ÁøÁ¤À» Çؾ߸¸ ÇÑ´Ù´Â °ÍÀº ÀúÈñ ÀÔÀåÀÌ ¾Æ´Õ´Ï´Ù. ´Ù¸¸ ¸¶ÃëÅëÁõÀÇÇаú Àü¹®ÀÇ°¡ ÇÁ·ÎÆ÷Æú ÁøÁ¤À» ÇÒ °æ¿ì °¡Àå optimalÇϹǷÎ, ÀÌ°Ô °¡´ÉÇϵµ·Ï MAC (Monitored Anesthesia Care) ¼ö°¡¸¦ ½Å¼³ÇØ´Þ¶ó´Â °ÍÀÔ´Ï´Ù.

ÃÖÁ¾ ÇÁ·ÎÆ÷Æú ÁøÁ¤ÀÇ ÁÖü ¼±ÅÃÀº ȯÀÚÀÇ ¼±ÅÃÀÇ ¸òÀ¸·Î ¸Ã±âÀÚ´Â °ÍÀÔ´Ï´Ù. µ·À» ´õ ³»°í(½Å¼³µÉ MAC ¼ö°¡·Î) ¸¶ÃëÅëÁõÀÇÇаú Àǻ翡°Ô ¹ÞµçÁö ¾Æ´Ï¸é ¾Æ´Ï¸é ÇöÇà ¼ö°¡´ë·Î Ÿ°ú Àǻ翡°Ô ¹ÞµçÁö. ¹°·Ð ÀÌ °æ¿ìµµ ÇÁ·ÎÆ÷Æú¿¡ ÇÑÇؼ­´Â ÇöÀçó·³ ÁøÁ¤ µ¿ÀǼ­/±â·ÏÁö/ȸº¹ °ü¸®Áö, ÁøÁ¤ Áß ÀûÀýÇÑ °¨½Ã, µ¶¸³µÈ ÁøÁ¤ °ü¸® ÀÇ·áÁø ¾øÀÌ´Â Çؼ­´Â ¾È µÇ°ÚÁÒ. »ç½Ç ¹Ì±¹ FDA, ¹Ì±¹ ¹× À¯·´ ¸¶Ãë°úÇÐȸÀÇ °ø½Ä ÀÔÀåÀº ÇÁ·ÎÆ÷Æú ÁøÁ¤Àº ¸¶Ãë°ú Àǻ縸ÀÌ ÇØ¾Æ ÇÑ´Ù´Â °ÍÀÌÁö¸¸ ÀúÈñ ½ÇÁ¤ »ó ÀÌ°ÍÀº ¹«¸®°¡ ÀÖ¾î º¸ÀÔ´Ï´Ù.


[2015-2-9. ¸¶Ãë°ú ¼±»ý´ÔÀÇ Ãß°¡ ´äº¯]

ÇÐȸ ÀÔÀåÀÌ Àß Àü´ÞµÈ °Í °°½À´Ï´Ù. '°£È£Á¶¹«»ç ¹èÁ¦' ºÎºÐÀº °³¿ø°¡ÀÇ Çö½ÇÀº ¾ËÁö¸¸, ÇâÁ¤½Å¼ºÀǾàÇ°À¸·Î ºÐ·ùµÈ ÇÁ·ÎÆ÷Æú Áֻ縦 ¾Æ¹«¸® Àǻ簡 Áö½Ã, °¨µ¶ÇÏ´õ¶óµµ °£È£Á¶¹«»ç°¡ ÁÖ»çÇϵµ·Ï ÇÑ´Ù´Â °ÍÀº ÀÇ·á¹ý À§¹ÝÀÔ´Ï´Ù. ¶ÇÇÑ ÁøÁ¤ Áß È¯ÀÚ °¨½Ã¸¸ º¸´õ¶óµµ °£È£Á¶¹«»çÀÇ ¾÷¹« ¹üÀ§¸¦ ³Ñ¾î¼­´Â ¾÷¹«¿µ¿ªÀÔ´Ï´Ù(¿ª½Ã ÀÇ·á¹ý À§¹ÝÀÌ¸ç ¿Ü±¹ÀÇ À¯»ç ±ÔÁ¤µµ ¾ø½À´Ï´Ù).


[FAQ]

[2015-2-9. EndoTODAY ¾Öµ¶ÀÚ ÀÇ°ß]

±³¼ö´Ô ¾È³çÇϽʴϱî? ¿À´ÃÀº ÇÁ·ÎÆ÷ÆúÀÇ ¹®Á¦Á¡À» ÀÚ±ØÀûÀ¸·Î ºÎ°¢½ÃŲ ¸¶Ãë°ú ±³¼ö´ÔÀÇ ³í¹® ³»¿ëÀÌ È­Á¦ÀÇ Á߽ɿ¡ ³õ¿© ÀÖ´Â °Í °°½À´Ï´Ù. ¿©±â¿¡ ´ëÇÑ ÀúÀÇ »ç°ßÀ» ¸»¾¸µå¸®°íÀÚ ÇÕ´Ï´Ù. Âü°í·Î Àú´Â ÇÁ·ÎÆ÷ÆúÀ» »ç¿ëÇÏ¿© À§´ëÀå³»½Ã°æÀ» ½ÃÇàÇÏ°í ÀÖ´Â ¿Ü°úÀÇ»çÀÔ´Ï´Ù.

¸ÕÀú »ó±âÀÇ ³í¹®Àº ÇÁ·ÎÆ÷ÆúÀ» »ç¿ëÇÑ °¢Á¾ Àü½Å ¹× ¼ö¸é ¸¶Ãë½Ã¿¡ »ç¸Á»ç°í°¡ ¸¹ÀÌ ¹ß»ýÇÑ´Ù°í ÁÖÀåÇÏ°í ÀÖ½À´Ï´Ù. ¾Æ¸¶ ¸Â´Â À̾߱âÀÏ °ÍÀÔ´Ï´Ù. ¿äÁò °ÅÀÇ ¸ðµç Àü½Å¸¶Ãë¿¡ À־ ÇÁ·ÎÆ÷ÆúÀ» ÀÌ¿ëÇÏ¿© ¼ö¼úÀ» À§ÇÑ ¸¶ÃëÀ¯µµ¸¦ ½ÃÇàÇÏ°í ÀÖ´Â °ÍÀ¸·Î ¾Ð´Ï´Ù.

¶ÇÇÑ Àü½Å ¸¶Ã븦 ¿äÇÏÁö ¾Ê´Â ºñ±³Àû °£´ÜÇÑ(?) ¼ö¼úÀ» À§ÇÑ ¼ö¸é¸¶Ãë¿¡µµ ÇÁ·ÎÆ÷ÆúÀ» ³Î¸® »ç¿ëÇÏ°í ÀÖ½À´Ï´Ù. ÀÌ¿¡ ÇØ´çÇÏ´Â ¼ö¼ú·Î´Â °¢Á¾ ¼ºÇü¼ö¼úµµ ÀÖ°í ¿Ü°ú ¿µ¿ªÀÇ ¼ö¼ú·Î´Â ·¹ÀÌÀú ÇÏÁö Á¤¸Æ·ù¼ö¼úÀ̳ª ´çÀÏ Ä¡Áú ¼ö¼ú µî¿¡¼­ »ç¿ëÇÏ°í ÀÖ½À´Ï´Ù. ¶Ç »çȸÀûÀ¸·Î ¹®Á¦°¡ µÇ°í ÀÖ´Â ÀÏÁ¾ÀÇ ±âºÐÀüȯÀ̳ª ÇÇ·Îȸº¹(?) À» À§ÇØ »ç¿ëÇÏ´Â °æ¿ìµµ ¸¹Àº °ÍÀ¸·Î ¾Ë°í ÀÖ½À´Ï´Ù. ƯÈ÷ ´ëÇк´¿øÀÌ ¾Æ´Ñ °³¿ø°¡ µî¿¡¼­ ÇÁ·ÎÆ÷ÆúÀº ¼ö¸é³»½Ã°æ ÀÌ¿ÜÀÇ ´Ù¾çÇÑ ¿ëµµ·Î »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

¸¶Ãë°ú Àü¹®ÀǵéÀÌ ÀÚ¹®ÇÏ¿´´Ù´Â ÇÁ·ÎÆ÷Æú °ü·Ã ÀÇ·á»ç°í¿¡´Â ¾Æ¸¶µµ ÀÌ·± heterogenous ÇÑ ´Ù¾çÇÑ °æ¿ì¸¦ Æ÷ÇÔÇÏ°í ÀÖÀ» °ÍÀÔ´Ï´Ù. ´ç¿¬È÷ ¹Ì´ÙÁ¹¶÷º¸´Ù ¸¹À» ¼ö ¹Û¿¡ ¾ø½À´Ï´Ù. ¹Ì´ÙÁ¹¶÷À¸·Î ¸¶Ã븦 ÇÏÁö´Â ¾ÊÀ»Å״ϱî¿ä. ºñ±³Àû Àþ°í °Ç°­ÇÑ »ç¶÷µé¿¡°Ô »ç°í°¡ ¹ß»ýÇÏ¿´´Ù´Â °Íµµ ÀÌ·± ¸Æ¶ô¿¡¼­ À¯ÃßµÉ ¼ö ÀÖ½À´Ï´Ù. ¼ºÇü¼ö¼úÀ̳ª ±âºÐÀüȯ ¸ñÀûÀ¸·Î »ç¿ëÇÏ´Â ¿¹µéÀÌ ´ëºÎºÐ Àþ°í °Ç°­ÇÑ »ç¶÷µéÀÏ °Å¶ó ½±°Ô Ãß·ÐÇÒ ¼ö ÀÖÀ» °ÍÀÔ´Ï´Ù. ±×·±µ¥ ±³¼ö´Ô²²¼­ "ÇÁ·ÎÆ÷ÆúÀ» »ç¿ëÇÑ ÁøÁ¤¿¡ ¹Ý´ëÇÏÁö ¾Ê´Â´Ù" °í ÇϽŠ°É º¸¸é ³í¹®¿¡ º¸°íµÈ ÇÁ·ÎÆ÷Æú »ç°í°¡ ´ëºÎºÐ ³»½Ã°æ °ü·Ã ÀÇ·á»ç°í¶ó°í »ý°¢ÇÏ°í °è½Å°Ô ¾Æ´ÑÁö ¸ð¸£°Ú½À´Ï´Ù. ±×·¸´Ù¸é ³»½Ã°æ¸¸À» ³õ°í º¸¾ÒÀ»¶§ 'ÇÁ·ÎÆ÷ÆúÀ» »ç¿ëÇÑ ¼ö¸é³»½Ã°æ¿¡¼­ ¹Ì´ÙÁ¹¶÷À» »ç¿ëÇÑ ¼ö¸é³»½Ã°æº¸´Ù ÀÇ·á»ç°í°¡ ÈξÀ ¸¹ÀÌ ÀϾ´Â°¡?'ÇÏ´Â Áú¹®¿¡ ´ëÇؼ­´Â Á¦ »ý°¢À¸·Î´Â ¾Æ´Ñ °Í °°½À´Ï´Ù.

¹Ì´ÙÁ¹¶÷Àº ÁÖ·Î ´ëÇк´¿ø¿¡¼­ »ç¿ëÇÏ°í ÀÖ°í ÇÁ·ÎÆ÷ÆúÀº ÁÖ·Î 2Â÷ º´¿ø ȤÀº °³¿ø°¡¿¡¼­ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÇ·á»ç°í°¡ ¹ß»ýÇÏ¿´À»¶§ °³¿ø°¡³ª 2Â÷ º´¿ø¿¡¼­ ´õ ¹®Á¦°¡ ºÎ°¢µÇ´Â °æ¿ì°¡ ¸¹°í ¹®Á¦ ³ëÃâºóµµµµ ´õ ³ô´Ù´Â °ÍÀÌ ¾èÀº ÀúÀÇ ¼Ò°ßÀÔ´Ï´Ù. Á¦ ÁÖº¯¿¡¼­ º¼ ¶§ ¹Ì´ÙÁ¹¶÷À¸·Î ÀÎÇÑ ÀÇ·á»ç°í°¡ ¾ø´Â °Íµµ ¾Æ´Ï°í °°Àº ¼¼Æðú Á¶°Ç¿¡¼­ ºñ±³ÇÒ ¼öµµ ¾ø¾î °á·Ð³»±â´Â ¾î·ÆÁö¸¸, Àú °³ÀÎÀûÀ¸·Î´Â ÇÁ·ÎÆ÷ÆúÀÌ ¾Ë·ÁÁø °Íº¸´Ù ¾ÈÀüÇÏ´Ù°í ´À³¢°í ÀÖ½À´Ï´Ù. ¹°·Ð ¹æ½ÉÇÏ¸é ¾ÈµË´Ï´Ù¸¸.....

ÁøÁ¤ ȤÀº ¼ö¸é³»½Ã°æ½Ã¿¡ ¸¶Ãë°úÀǻ簡 ÇÊ¿äÇÑ°¡? ¶ó´Â Áú¹®¿¡µµ ºÎÁ¤ÀûÀÔ´Ï´Ù. ¸¸¾à ±×·¸´Ù°í ÇÑ´Ù¸é ¾Æ¸¶ ¸¶Ãë°ú Àü¹®ÀÇÀÇ ¼ö¿ä°¡ ±ÞÁõÇؼ­ ¸¶Ãë°úÀÇ»ç´Â »óÁ¾°¡¸¦ Ä¡°Ô µÇ°ÚÁö¸¸¿ä.

³»½Ã°æÀÇ»ç´Â ³»½Ã°æ ¼ú±â¿¡µµ ´É¼÷ÇÏ°í, ¼ÒÈ­±â ÁúȯÀÇ Áø´Ü, Ä¡·á, º´¸® µî¿¡µµ Á¤ÅëÇÏ¸ç ½Ã¼ú ÁßÀÇ ¿©·¯ »óȲ¿¡ ´ëó´É·Âµµ µÎ·ç °®Ãß¾î¾ß ÇÒ °Å¶ó ¹Ï½À´Ï´Ù. ³»½Ã°æ Àǻ簡 ³»½Ã°æ È­¸é¸¸ µé¿©´Ù º¸°í ¸ð´ÏÅ͸µÀº Àß ¸ô¶ó ´©±º°¡¿¡°Ô ¸Ã±ä´Ù¸é ¾Æ¸¶ ¹ÝÂÊÂ¥¸® Àü¹®°¡°¡ ¾Æ´Ò±î »ý°¢ÇÕ´Ï´Ù. ¼ö·Ã°úÁ¤¿¡¼­ ´Ù ´Ù·ç´Â ¹ÙÀÌÅ»°ú ABC ¸¦ ¿Ö ¸¶Ãë°úÀǻ翡°Ô¸¸ ¸Ã°Ü¾ß ÇÏ´ÂÁö? ¼ö¼úÀ§ÇÑ Àü½Å¸¶Ãëµµ ¾Æ´Ñµ¥ ¸»ÀÔ´Ï´Ù. ÀÌ·± ³íÀÇ´Â ¿ì¸®³ª¶ó¸¸ÀÇ Æ¯¼öÇÑ »óȲ¶§¹®ÀÎ °Í °°½À´Ï´Ù.

³»½Ã°æÀÇ»ç´Â ÀÚ½ÅÀÌ »ç¿ëÇÏ´Â ÁøÁ¤Á¦¿¡ ´ëÇØ Àß ¾Ë°í ´ëó´É·ÂÀ» Å°¿ì°í, ¼ö¼ú ¹× ±âŸ ¸ñÀûÀ¸·Î ÇÁ·ÎÆ÷ÆúÀ» »ç¿ëÇÏ´Â º´¿ø¿¡¼­´Â Àü¹®ÀηÂÀ» È®º¸ÇÏ¸ç ¹«¾ùº¸´Ùµµ ÇÁ·ÎÆ÷ÆúÀÇ ¿À³²¿ëÀ» ¾ø¾Öµµ·Ï ÇØ¾ß ÇÏ°Ú½À´Ï´Ù. ÇÏÁö¸¸ ÁøÁ¤³»½Ã°æ¿¡¼­ ÇÁ·ÎÆ÷ÆúÀ» Ÿ±âÇÑ´ÙµçÁö, ¸¶Ãë°úÀǻ縸ÀÌ ÇÁ·ÎÆ÷ÆúÀ» ´Ù·ç¾î¾ß ÇÑ´ÙµçÁö ÇÏ´Â ³íÀÇ´Â ¿ÇÁö ¾ÊÀº °Í °°½À´Ï´Ù. °¨»çÇÕ´Ï´Ù.


[2015-2-10. EndoTODAY ¾Öµ¶ÀÚ ÀÇ°ß]

º¸±â¸¸ ÇÏ´Ù°¡, ¸î ÀÚ ÀÇ°ßÀ» º¸³À´Ï´Ù.³íÁ¡ (Àü´ã ÀÇ·áÀÎ)°ú ¹þ¾î³­ °ÍÀÔ´Ï´Ù. ¹Ì±¹ FDA, ¹Ì±¹ ¹× À¯·´ ¸¶Ãë°úÇÐȸÀÇ °ø½Ä ÀÔÀå ºÎºÐ¿¡ ´ëÇؼ­´Â Àß ¸ð¸£°ÚÁö¸¸, Á¦°¡ ¿¬¼ö °æÇèÀÌ ÀÖ¾ú´ø californiaÀÇ °æ¿ì ¸¸À» º¸¸é, ¸¶Ãë°ú Àǻ簡 ¾Æ´Ï´õ¶óµµ general anesthesia permitÀ» °¡Áö°í ÀÖÀ¸¸é profopol sedationÀ» ÇÒ ¼ö ÀÖ½À´Ï´Ù. Ãëµæ ¹æ¹ýÀº ¼ö·ÃÇÁ·Î±×·¥ÀÌ ±³À° ³»¿ëÀ» Æ÷ÇÔÇÏ°í ÀÖÀ¸¸é ÃëµæÇÒ ¼ö ÀÖ°í, ÁÖÁ¤ºÎ¿¡¼­ ÀÎÁ¤ÇÏ´Â ±³À°À» µè°í ½ÃÇèÀ» º¸¸é ÃëµæÇÒ ¼öµµ ÀÖ¾ú½À´Ï´Ù (ÁÖÁ¤ºÎÀÇ ±ÔÁ¤¿¡ ¸í½ÃµÇ¾î ÀÖ½À´Ï´Ù). Ãëµæ ÈÄ¿¡µµ º¸¼ö±³À° ±ÔÁ¤°ú °ü¸® ±ÔÁ¤ÀÌ ±î´Ù·Ó½À´Ï´Ù. ±×·±µ¥ º¸¼ö±³À°Àº ¸¶Ãë°ú Àǻ簡 ÇÕ´Ï´Ù. º¸¼ö±³À°À» ´ã´çÇÏ´Â °ÍÀÌ ¹Ì±¹¸¶ÃëÇÐȸ °ø½Ä ÀÔÀåÀÌ ¾Æ´Ñ Áö´Â ¸ð¸£°Ú½À´Ï´Ù.


[2015-2-10. ÀÌÁØÇà ´äº¯]

ÁÁÀº ÀÇ°ß °¨»çÇÕ´Ï´Ù. ¸î °¡Áö·Î ¿ä¾àÇÏ¿© Á¦ »ý°¢À» ½á º¸¾Ò½À´Ï´Ù.

1. ¸¶Ãë°ú Àǻ縸 ÇÁ·ÎÆ÷ÆúÀ» »ç¿ëÇØ¾ß Çϴ°¡?

¹Ì±¹À̳ª À¯·´¿¡¼­µµ ½Î¿ì°í ÀÖ´Â À̽´ÀÔ´Ï´Ù. ¿ì¸®³ª¶ó ¸¶Ãë°ú ¼±»ý´Ôµéµµ ¸î ³â Àü±îÁö´Â ¸¶Ãë°ú Àǻ縸 ÇÁ·ÎÆ÷ÆúÀ» ½á¾ß ÇÑ´Ù°í ÁÖÀåÇÏ¿´½À´Ï´Ù. ±×·±µ¥ ¾ó¸¶ ÀüºÎÅÍ´Â ÀÌ·¯ÇÑ ÁÖÀåÀ» öȸÇÏ¿´½À´Ï´Ù. ¸¶Ãë°ú ÀÇ»çµéÀÌ ÇÁ·ÎÆ÷ÆúÀ» ÀÌ¿ëÇÑ ¸¶Ã븦 ÇÏ¿´À» ¶§¿¡´Â 'MAC ¸¶Ãë'¶ó´Â º°µµÀÇ ¼ö°¡¸¦ »êÁ¤ÇØ ´Þ¶ó´Â ÂÊÀ¸·Î ¹æÇâÀ» ¹Ù²Û °ÍÀÔ´Ï´Ù. ´Ù¸¸ ¸¶Ãë°ú°¡ ¾Æ´Ñ Àǻ簡 ÇÁ·ÎÆ÷ÆúÀ» »ç¿ëÇÒ ¶§¿¡´Â ´ÙÀ½ÀÇ µÎ Á¶°ÇÀ» ÁöÅ°´Â °ÍÀÌ ÁÁ°Ú´Ù°í Á¦¾ÈÇÏ°í ÀÖ½À´Ï´Ù. µû¶ó¼­ ÀÌÁ¦´Â ¸¶Ãë°ú ÀÇ»ç³Ä ¾Æ´Ï³Ä·Î ½Î¿ï ÀÏÀº ¾Æ´Ï¶ó°í º¾´Ï´Ù.

1) ÇÁ·ÎÆ÷Æú ¼ö¸é¸¶Ãë´Â Ÿ ÁøÁ¤Á¦ »ç¿ë ¼ö¸é¸¶Ãë¿Í ºÐ¸®ÇÏ¿© Àü½Å¸¶Ãë¿¡ ÁØÇÏ´Â °ü¸®°¡ ÇÊ¿äÇÏ´Ù.

2) ÇÁ·ÎÆ÷Æú ¼ö¸é¸¶Ãë ½Ã´Â ¹Ýµå½Ã "½Ã¼ú°ú ¹«°üÇÑ µ¶¸³ÀûÀÎ ¼ö¸é ¸¶Ãë Àü´ã ÀÇ·áÁø(¼ÒÁ¤ÀÇ ±³À°À» ¹ÞÀº ÀÇ»ç ¶Ç´Â °£È£»ç)"ÀÌ ¹Ýµå½Ã Á¸ÀçÇØ¾ß ÇÑ´Ù.

2. ÇÁ·ÎÆ÷Æú »ç°í Áß ³»½Ã°æÀÌ Â÷ÁöÇÏ´Â ºñÁß

¾Öµ¶ÀÚ²²¼­ "'ÇÁ·ÎÆ÷ÆúÀ» »ç¿ëÇÑ ÁøÁ¤¿¡ ¹Ý´ëÇÏÁö ¾Ê´Â´Ù'°í ÇϽŠ°É º¸¸é ³í¹®¿¡ º¸°íµÈ ÇÁ·ÎÆ÷Æú »ç°í°¡ ´ëºÎºÐ ³»½Ã°æ °ü·Ã ÀÇ·á»ç°í¶ó°í »ý°¢ÇÏ°í °è½Å°Ô ¾Æ´ÑÁö ¸ð¸£°Ú½À´Ï´Ù"¶ó°í ¾ð±ÞÇϼÌÁö¸¸ »ç½Ç ³»½Ã°æ °ü·Ã »ç°í´Â ÇÁ·ÎÆ÷Æú »ç°íÀÇ ÀϺÎÀÏ »ÓÀÔ´Ï´Ù. Àú´Â ³»½Ã°æ ºÐ¾ß¿¡ ´ëÇؼ­¸¸ ÀÇ°ßÀ» ³»°í ½Í½À´Ï´Ù. ±×·¡¼­ ±×·± Ç¥ÇöÀ» ½è½À´Ï´Ù. Àß ¾ËÁö ¸øÇÏ´Â ¿µ¿ª¿¡ ´ëÇÏ¿© ¹ß¾ðÇÏ´Â °ÍÀº ÀûÀýÇÏÁö ¾Ê´Ù°í »ý°¢µÇ±â ¶§¹®ÀÔ´Ï´Ù.

ÇÁ·ÎÆ÷ÆúÀ» »ç¿ëÇÑ ³»½Ã°æ µµÁß ÇÕº´ÁõÀÌ ¹ß»ýÇÑ ¿¹´Â »ó´ç¼ö ¹«Áõ»ó ¼ºÀÎÀÇ °Ç°­°ËÁøÀ̾ú½À´Ï´Ù. °Ç°­°ËÁøÀ» À§ÇÏ¿© ÇÁ·ÎÆ÷ÆúÀ» ¸Â´Ù°¡ »ç°í°¡ ³ª¸é Á¤¸» Å« ÀÏÀÔ´Ï´Ù (»ç°íÀÇ »ó´ç¼ö´Â »ç¸ÁÀÔ´Ï´Ù). ±×·¡¼­ Á¦°¡ ÇÁ·ÎÆ÷ÆúÀ» »ç¿ëÇÑ ÁøÁ¤³»½Ã°æ¿¡ ¹Ý´ëÇÏÁö ¾ÊÁö¸¸ ±×·¡µµ ¾öû, ¸Å¿ì ¾öû Á¶½ÉÇØ¾ß ÇÑ´Ù°í °­Á¶ÇÏ°í ÀÖÀ» »ÓÀÔ´Ï´Ù. ¸¶Ãë°úÀÇ ±ÇÀ¯¸¦ ÁöÅ°´Â °ÍÀÌ ÁÁ°Ú½À´Ï´Ù.

3. ÇÁ·ÎÆ÷ÆúÀ» »ç¿ëÇÑ ¼ö¸é³»½Ã°æ¿¡¼­ ¹Ì´ÙÁ¹¶÷À» »ç¿ëÇÑ ¼ö¸é³»½Ã°æº¸´Ù ÀÇ·á»ç°í°¡ ÈξÀ ¸¹ÀÌ ÀϾ´Â°¡?

Àú´Â ¹Ì´ÙÁ¹¶÷º¸´Ù ÇÁ·ÎÆ÷Æú¿¡¼­ »ç°í°¡ ¸¹´Ù°í »ý°¢ÇÏ°í ÀÖ½À´Ï´Ù. µ¥ÀÌŸ´Â ¾ø½À´Ï´Ù. ±×³É ÊïÀÔ´Ï´Ù. »ç½Ç ¾ð·Ð¿¡ ³ª¿À´Â ´ëºÎºÐÀÇ »ç°í´Â ÇÁ·ÎÆ÷ÆúÀÔ´Ï´Ù.

À§ÇèÇÑ ¼ö¼úÀº ´ëÇк´¿ø¿¡¼­ ÇÏ°í, ÀÛ°í °£´ÜÇÑ ¼ö¼úÀº ÀÛÀº º´¿ø¿¡¼­ ÇÏ´Â °ÍÀÌ º¸ÅëÀÔ´Ï´Ù. À§ÇèÇÑ ¾àÀº ´ëÇк´¿ø¿¡¼­ »ç¿ëÇÏ°í, ¾ÈÀüÇÑ ¾àÀº Á» ´õ ÀÛÀº º´¿ø¿¡¼­ »ç¿ëÇÏ´Â °ÍÀÌ ´ç¿¬ÇÑ ÀÏÀÔ´Ï´Ù. ±×·±µ¥ ÇÁ·ÎÆ÷ÆúÀº Á¤¹Ý´ë·Î µ¹¾Æ°¡°í ÀÖ½À´Ï´Ù. ´ëÇк´¿ø ÀÇ»çÀÎ Àú´Â ³Ê¹« À§ÇèÇÏ´Ù°í »ý°¢ÇÏ¿© »ç¿ëÇÏÁö ¾Ê°í ÀÖ½À´Ï´Ù. °³Àκ´¿ø¿¡¼­´Â ³Î¸® »ç¿ëµÇ°í ÀÖÁö¸¸.... ÇÁ·ÎÆ÷Æú °ü·ÃµÈ Çö »óȲÀº ºÐ¸í ºñÁ¤»óÀÔ´Ï´Ù.

4. °³ÀÎÀûÀ¸·Î ÇÁ·ÎÆ÷ÆúÀÌ ¾ÈÀüÇÏ´Ù°í ´À³¢´Â ¼±»ý´Ôµé¿¡ ´ëÇÏ¿©

10,000°Ç Áß Çϳª, 100,000°Ç Áß Çϳª, 1,000,000°Ç Áß ´Ü ÇϳªÀÇ »ç°í°¡ ÀÖ´õ¶óµµ À§ÇèÇÏ´Ù°í º¸´Â °ÍÀÌ ÁÁ½À´Ï´Ù. ƯÈ÷ ±× °á°ú°¡ »ç¸ÁÀÎ °æ¿ì¿¡´Â.... °³ÀÎÀÇ ÇÑÁ¤µÈ °æÇèÀ¸·Î ¾ÈÀüÀ» ¸»ÇÒ ¼ö ÀÖ´Â ±×·± ÀÏÀÌ ¾Æ´Õ´Ï´Ù.

±¹°¡ Â÷¿øÀÇ Åë°è¸¦ ºÁ¾ßÇÏ´Â °ÍÀÌ ¾ÈÀü À̽´ÀÔ´Ï´Ù. ºñ·Ï ³» ȯÀÚ´Â ¾ÆÁ÷ ¾Æ¹« ¹®Á¦°¡ ¾ø¾úÁö¸¸, ´Ù¸¥ º´¿ø,´Ù¸¥ ¼±»ý´Ô ȯÀÚ Áß ÇÁ·ÎÆ÷Æú ³»½Ã°æÀ» ¹Þ´Ù°¡ »ç¸ÁÇÑ È¯ÀÚ°¡ Á¾Á¾ ÀÖ´Ù¸é ±×°Ç À§ÇèÇÑ °ÍÀÔ´Ï´Ù. ³Ê¹« ½±°Ô ¾ÈÀüÇÏ´Ù°í »ý°¢ÇÏÁö ¸¶½Ã±â¸¦ ±ÇÇÕ´Ï´Ù.

Àü ±¹¹ÎÀÌ ¸ðµÎ Çѹø¾¿ ³»½Ã°æÀ» ¹Þ´õ¶ó°í ´Ü ÇϳªÀÇ ÇÁ·ÎÆ÷Æúl °ü·Ã »ç¸Á·Ê°¡ ³ª¿À¸é ¾È µÈ´Ù´Â °ÍÀÌ Á¦ »ý°¢ÀÔ´Ï´Ù. ÀÌ Á¤µµ°¡ µÇÁö ¾ÊÀ¸¸é À§ÇèÇÏ´Ù°í º¸´Â °ÍÀÌ ¸Â½À´Ï´Ù.

"±³Åë»ç°í ¸î °Ç ÀÖ¾ú´Ù°í ÀÚµ¿Â÷¸¦ ¾ø¾Ø´Ù´Â °ÍÀÌ ¸»ÀÌ µÇ´À³Ä?"¿Í´Â ÀüÇô ´Ù¸¥ À̾߱âÀÔ´Ï´Ù. ¾àÀº ´Ù¸¨´Ï´Ù. ¾àÀ¸·Î ÀÎÇÏ¿© »ç¸Á»ç°í°¡ ¸î °Ç ÀÖÀ¸¸é ±× ¾àÀ» ÅðÃâ½Ãų ¼öµµ ÀÖ´Â ÀÏÀÔ´Ï´Ù. Prepulsid (cisapride)°¡ ±×·¨°í Vioxx(rofecoxib)µµ ±×·¨½À´Ï´Ù. ÅðÃâÀº ¾Æ´Ï´õ¶óµµ ¾ö°ÝÇÑ Á¦ÇÑÀ» µÐ »óÅ¿¡¼­ »ç¿ëÇÒ ¼ö ÀÖµµ·Ï Á¤ÇÒ ¼öµµ ÀÖ½À´Ï´Ù. ÀÌ·¸°Ô º¸¸é ¾î¶»°Ú½À´Ï±î? (¾î¶² ¸ðµ¨ÀÇ ÀÚµ¿Â÷°¡ ÀÚ²Ù »ç°í¸¦ ³»¸é ±× ¸ðµ¨Àº ÅðÃâ½Ãų ¼ö ÀÖ½À´Ï´Ù. ÀÚµ¿Â÷ Àüü¸¦ ¾ø¾Ö´Â °ÍÀÌ ¾Æ´Ï°í. ¾î¶² ¾àÀÌ ÀÚ²Ù »ç°í¸¦ ³»¸é ±× ¾àÀº ÅðÃâ½Ãų ¼ö ÀÖ½À´Ï´Ù. ¾à Àüü°¡ ¾Æ´Ï°í.)°¨Á¤ÀûÀ¸·Î ´ëÀÀÇÒ ÀÏÀº ¾Æ´Ï¶ó°í º¾´Ï´Ù.

5. °¡Àå ¶ß°Å¿î À̽´´Â ¹«¾ùÀΰ¡?

°¡Àå ¶ß°Å¿î À̽´´Â '¸¶Ãë°ú¿¡¼­ ±ÇÇÏ´Â minimumÀ» ¿ì¸®³ª¶ó ÀÇ·áÇö½Ç¿¡¼­ Áöų ¼ö Àִ°¡?'·Î ¿ä¾àµË´Ï´Ù. ÇÁ·ÎÆ÷ÆúÀº ¿ö³« °­ÇÏ°í onsetÀÌ ºü¸£±â ¶§¹®¿¡ ȯÀÚ´Â continuous monitoring »óÅ¿¡ ³õ¿© ÀÖ¾î¾ß ÇÑ´Ù´Â °ÍÀÔ´Ï´Ù. ±×³É pulse oximeter Çϳª¸¦ ¼Õ°¡¶ô¿¡ °É¾î³õ´Â °ÍÀº ºÎÁ·ÇÕ´Ï´Ù. ¹Ýµå½Ã ´©±º°¡ Áö¼ÓÀûÀ¸·Î ÁöÄѺ¸°í ÀÖ¾î¾ß ÇÕ´Ï´Ù. Àü½Å¸¶Ãë¿Í ¸¶Âù°¡Áö·Î... ½Ã¼ú¿¡ Âü¿©ÇÏÁö ¾Ê´Â ÀÇ»ç ȤÀº °£È£»ç°¡ continuous monitoringÀ» ÇØ¾ß ÇÕ´Ï´Ù.

Áï propofolÀ» ÀÌ¿ëÇÑ ÁøÁ¤»óÅ¿¡¼­ ³»½Ã°æ °Ë»ç¸¦ ÇÏ·Á¸é Àû¾îµµ 3¸íÀÌ ÇÊ¿äÇÕ´Ï´Ù. (1) ³»½Ã°æ ½Ã¼úÀÚÀÎ ÀÇ»ç, (2) ³»½Ã°æ º¸Á¶ÀÚ (ÀÇ»ç, °£È£»ç, °£È£Á¶¹«»ç), (3) Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ(uninterrupted continous monitoring)À» ÇÏ´Â ÀÇ·áÀÎ (ÀÇ»ç ȤÀº °£È£»ç). Å« º´¿ø¿¡¼­´Â ÀÌ·¸°Ô ÇÒ ¼ö ÀÖÀ»Áö ¸ð¸¨´Ï´Ù. ±×·±µ¥ °³¾÷°¡¿¡¼­ ÀÌ·¸°Ô ÇÒ ¼ö ÀÖÀ»±î¿ä? ´ëÇк´¿ø¿¡¼­µµ ±×·¸°Ô Çϱ⠾î·Æ½À´Ï´Ù (±×·¡¼­ Àú´Â ÇÁ·ÎÆ÷ÆúÀ» ¾²Áö ¾Ê½À´Ï´Ù). ÀÌ°ÍÀÌ °¡Àå ¶ß°Å¿î À̽´ÀÔ´Ï´Ù.

¸¶Ãë°ú¿¡¼­ ±ÇÇÏ´Â ¹Ù°¡ Áö³ªÄ£ °ÍÀº ¾Æ´Õ´Ï´Ù. ¾î´À Ã¥À» º¸¾Æµµ, ¾î´À ¸®ºä¸¦ º¸¾Æµµ, ¾î´À Àü¹®°¡ À̾߱⸦ µé¾îº¸¾Æµµ minimunÀº 'ÀÇ·áÀο¡ ÀÇÇÑ Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ(uninterrupted continous monitoring)'À̱⠶§¹®ÀÔ´Ï´Ù. °áÄÚ °úÇÑ °ÍÀÌ ¾Æ´Õ´Ï´Ù. ¹®Á¦´Â ¿ì¸®³ª¶óÀÇ ÇüÆí¾ø´Â ÀÇ·á Çö½ÇÀÌÁö¿ä.

°á·ÐÀº ¾ø½À´Ï´Ù. ¾îÂ¥ÇÇ Á¦°¡ Á¤¸®ÇØ µå¸± ¼ö ÀÖ´Â °Íµµ ¾Æ´Õ´Ï´Ù. ÁúÁÁ°í ¾ÈÀüÇÑ ÀǷḦ ÇÏ·Á¸é ÃÖ¼ÒÇÑÀÇ µ·ÀÌ ÇÊ¿äÇÕ´Ï´Ù. ¸¶Ãë°ú¿¡¼­ ±ÇÇÏ´Â ÇÁ·ÎÆ÷Æú »ç¿ëÀÇ ÃÖ¼Ò Á¶°ÇÀ» ÁöÅ°·Á¸é ¸¹Àº °í±Þ ÀηÂÀÌ ÅõÀԵǾî¾ß ÇÕ´Ï´Ù (3¸íÀÌ µ¿¿øµÇ¾î¾ß °Ü¿ì ³»½Ã°æÀ» ÇÒ ¼ö ÀÖ½À´Ï´Ù). »ó´çÇÑ ºñ¿ëÀÌ µé¾î°¡´Â ¼ÀÀÌÁö¿ä. ºÐÀ§±â´Â µ· À̾߱⸦ ²¨³¾ ¼öµµ ¾øÀ¸´Ï...... ±×·¡¼­ Àú´Â ÇÁ·ÎÆ÷ÆúÀ» »ç¿ëÇÏÁö ¾Ê½À´Ï´Ù. 'À§ÇèÇÏ°Ô ÇÏ´À´Ï Â÷¶ó¸® ÇÏÁö ¸»ÀÚ'ÀÇ Ã¶ÇÐÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ´ëÇб³¼ö¸¸ °¡Áú ¼ö ÀÖ´Â °³¶ËöÇÐÀ̶ó°í ¿åÇصµ ÁÁ½À´Ï´Ù. ¿©ÇÏÆ° ¾ÈÇÕ´Ï´Ù. ¸¶Ãë°ú¿¡¼­ ±ÇÇÏ´Â minimumÀ» Áöų ¼ö Àִ ȯ°æÀÌ ¾Æ´Ï´Ï±î...

PS. À̼ºÀûÀÎ ´ëÃ¥À» ¸¶·ÃÇØ¾ß ÇÕ´Ï´Ù. ±×·¸Áö ¾ÊÀ¸¸é °è¼Ó ¾ð·Ð¿¡ ÀÌ·± º¸µµ°¡ ³ª¿É´Ï´Ù. ÃÖ±Ù ±â»ç Çϳª ¼Ò°³ÇÕ´Ï´Ù. Á¦¸ñÀº '°Ç°­°ËÁø ¼ö¸é³»½Ã°æµµ À§Çè'


[References]

1) EndoTODAY ³»½Ã°æ ÁøÁ¤

© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Jun Haeng Lee.